Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and restated in July 2024, with a targeted close for later this year.

Highlights of the report show that Evofem saw improved loss from operations by 81% with net product sales increasing 69% in the quarter, totaling $4.2 million compared to $2.5 million in the prior year period. Corporate highlights for the period included the acquisition of SOLOSEC, a commercially attractive, single-dose, FDA-approved oral antibiotic designed to treat two pervasive sexual health infections; the licensing agreement for commercial rights of Phexxi(R) in the Middle East; and a partnership with Hello Alpha, a leading telemedicine company, to add Phexxi to its commercial offering.

“Evofem continues to prove that with a disciplined and committed team we can maneuver through challenges in the market and successfully execute our strategy to expand and diversify our revenue stream,” said Evofem Biosciences CEO Saundra Pelletier in the press release. “Women don’t need more choices, they need better ones, and Evofem will continue to deliver on that promise.”

To view the full press release, visit https://ibn.fm/WWL7r

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” In December 2023, Aditxt entered into a merger agreement with Evofem under which Aditxt intends to acquire Evofem. The parties reinstated and amended the merger agreement in May 2024 and are working to close the contemplated transaction in the second half of 2024. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN